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induced platelet inhibition ratio<30% (1.2% vs 8.2%, P<0.05). There
were signiﬁcant differences between clopidogrel group and ticagrelor
group in the percentages of patients with ADP-induced platelet inhi-
bition ratio <50% (29.4% vs 10.6%, P<0.05). There were also signiﬁ-
cant differences between clopidogrel group and ticagrelor group in
the percentages of patients with ADP-induced platelet inhibition
ratio>75% (41.8% vs 69.4%, P<0.05).
CONCLUSIONS ① Ticagrelor had greater inhibitory effect on the pa-
tients with ACS after PCI than Clopidogrel. ② Higher residual platelet
activity (HRPA) phenomenon also can be seen in the ticagrelor treatment
patients, although that is evenmore in clopidogrel treatment patients.
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OBJECTIVES The purpose of this study was to perform a meta-anal-
ysis comparing short-term versus long-term dual antiplatelet therapy
(DAPT) to identify the optimal duration of DAPT in patients with Drug-
Eluting Stent (DES) implantation.
METHODS This study included 15,870 patients from 7 randomized
clinical trials (RCT) comparing short-term DATP (S-DAPT) versus long-
term DATP (L-DAPT) following drug-eluting stents. We examined the
odds ratio (OR) and 95% conﬁdence intervals (Cls) of clinically sig-
niﬁcant bleeding (CSB) and stent thrombosis as primary endpoints.
Myocardial infarction, stroke, cardiovascular mortality and all-cause
mortality were evaluated as secondary endpoints.
RESULTS Compared with L-DAPT, S-DAPT had a decreased risk of CSB
(OR: 0.57 [95% CI: 0.40 to 0.81]; p < 0.01). The rates of stent throm-
bosis (OR: 1.20 [95% CI: 0.77 to 1.88]; p > 0.05), myocardial infarction
(OR: 1.13 [95% CI: 0.88 to 1.44]; p > 0.05), stroke (OR: 0.88 [95% CI:
0.57 to 1.36]; p > 0.05), cardiovascular mortality (OR: 0.99 [95% CI:
0.72 to 1.36]; p > 0.05) and all-cause mortality (OR: 0.93 [95% CI: 0.74
to 1.18]; p > 0.05) were similar.
CONCLUSIONS S-DAPT for treatment in patients with DES implanta-
tion is associated with a signiﬁcant reduction of CSB compared with
L-DAPT.
GW26-e4591
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OBJECTIVES The ezetimibe/simvastatin combination tablet and high-
dose simvastatin monotherapy represent two major options for treat-
ment of patients with hyercholesterolemia. The lowering lipid effect of
direct comparative studies between ezetimibe/simvastatin (10/10mg)
and high-dose simvastatin(40mg or 80mg) therapies have not been
reported. To evaluate whether low-dose simvastatin/ezetimibe 10/
10mg would achieve the same lowering lipid efﬁcacy compared to
simvastatin 40mg or 80mg in treatment of patients with dyslipidemia.
METHODS Randomized controlled trials (RCTs) regarding to the pa-
tients with dyslipidemia in treatment of ezetimibe and simvastatin
were retrieved in PubMed, EMBASE and Cochrane Central Register of
Controlled Trials (CENTRAL). We also searched the reference lists of
relevant papers. Data was extracted by two reviewers independently.
Statistical analysis was performed using RevMan 5.2.
RESULTS 8 RCTs including 202 high-dose simvastatin controls and
200 low-dose simvastatin / ezetimibe patients were enrolled in our
meta-analysis. Low density lipoprotein - cholesterol (MD, -0.27; 95%
CI, -3.82 to 3.28; P ¼0.88), high density lipoprotein-cholesterol
(MD, 0.32; 95%CI, -1.32 to 1.95; P ¼0.88), the total cholesterol
level (MD, 0.76; 95%CI, -4.14 to 5.65; P ¼0.76), Apolipoprotein B (MD,
-1.70; 95 %CI, -7.10 to 3.71; P ¼0.54) and apolipoprotein A-I level (MD,
-2.75; 95%CI, -9.72 to 4.23; P ¼0.44) were at the same level after the
low-dose ezetimibe / simvastatin 10/10mg and simvastatin 40mg or 80
mg treatment respectively. However, the maximal dose of simvastatin
can reduce the teriglyrides effectively compared to low-dose simva-
statin/ezetimibe (MD, 14.35; 95%CI, 9.51 to 19.20; P <0.00001).
CONCLUSIONS Our study demonstrate ezetimibe/simvastatin
10/10mg can reach the same lowering lipid parameters such as LDL-C,total cholesterol, Apoliprotein B compared to the maximal-dose sim-
vastin 40mg or 80 mg. These results suggest that ezetimibe/simva-
statin 10/10mg is comparable to the high-dose simvastatin 40mg or
80mg, however, the maximal dose of simvastatin can reduce the tri-
glycerides effectively compared to low-dose simvastatin/ezetimibe.
Two agents can reduce ApoB level and increase the anti-atheroscle-
rosis lipidprotein ApoA-I, and two treatment strategies have same
favorable effect on lipoprotein proﬁles.
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OBJECTIVES To examine the efﬁcacy and safety of tolvaptan in acute
decompensated heart failure patients with reduced left ventricular
systolic function.
METHODS A total of 145 hospitalized acute decompensated heart
failure patients were randomly assigned to either a tolvaptan(n¼79) or
a control group(n¼66) which used conventional treatment only.
Baseline clinical characteristics were not different between the two
groups. We divided these patients based on the left ventricular ejec-
tion fraction (EF) by echocardiography.
RESULTS There was no signiﬁcant difference of daily urine volume
between the tolvaptan and control groups in patients with preserved
EF ( 50%).The urine volume was signiﬁcantly higher in the tolvaptan
group than in the control group in those with reduced EF (< 50%)(P <
0.05 ).In the safety proﬁle, the incidence rate of thirst was higher in
the tolvaptan group than that in control group (21.5% versus 7.6%,
P<0.05). The incidence of hypernatremia( 150 mEq/L) in tolvaptan
group was no signiﬁcant difference than that in control group (6.3%
versus 3.0%, P>0.05).
CONCLUSIONS This study reveals that tolvaptan is more effec-
tive than conventional treatment in acute decompensated heart failure
patients with reduced left ventricular systolic function and it is safety.
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OBJECTIVES To investigate the efﬁcacy and safety of Shenson-
gyangxin capsule (SSYX) on heart rate variability (HRV) and insomnia
in maintenance hemodialysis patients.
METHODS sixty-three maintenance hemodialysis patients in the third
afﬁliated hospital of Sun Yat-Sen University from 2013 June to
December were divided into two groups, SSYX treatment group(n¼33)
and control group(n¼30). SSYX treatment group were received SSYX 4
capsules four times a day for eight weeks, all patients received 24-h-
holter test and Pittsburgh sleep quality index were measured at both
baseline and eight weeks in these sixty-three patients.
RESULTS SSYX can improve heart rate variability [SDNN (93.21.4)
vs.(82.413.1) ms, SDNNi (41.212.8) vs. (28.412.2)ms, SDANNi
(81.321.1) vs. (73.220.7)ms, RMSSD (28.313.2)vs.(21.811.9)ms,
PNN50 (9.67.1) vs.(7.15.8)%, P<0.05], SSYX can decrease the inci-
dence of arrhythmia [premature atrial contraction(60.6% vs.24.2%),
atrial tachycardia (45.5% vs.12.1%), premature ventricular contrac-
tion(9.1% vs.3%), ventricular tachycardia(21.2% vs.9.1%), atrial-ven-
tricular blocker (60.6% vs.24.2%), P<0.05], SSYX also improved sleep
quality signiﬁcantly[PSQI (6.282.12) vs.( 14.392.84), P<0.05]. There
was no severe adverse events registered during the study.
CONCLUSIONS Clinical use of SSYX was safe and effective for treating
hemodialysis patients with decrease HRV and insomnia.
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OBJECTIVES To report the effects of dabigatran etexilate on routine
coagulation assays in two aged patients with atrial ﬁbrillation.
METHODS The data of routine coagulation assays from two aged cases
treated with dabigatran etexilate were retrospectively reviewed,
